A n estimated 9 million people contracted Mycobacterium tuberculosis in 2013, with a further 1.5 million deaths attributed to tuberculosis (TB) infection and coinfection with HIV (1) . Vaccination is widely accepted to be the most effective method for control of an infectious disease. The current TB vaccine, Mycobacterium bovis BCG, is most commonly delivered as an intradermal (i.d.) injection. It is known to reduce the occurrence of disseminated forms of childhood TB (2) but displays variable efficacy against the infectious forms of adult pulmonary disease, suggesting that BCG-induced immunity may decline over time (3, 4) . While several novel vaccines have progressed to clinical trials (5) , none has yet improved upon the limited protection afforded by intradermal BCG vaccination. Typically, novel vaccines are delivered via a parenteral route, and, consequently, attention is now refocused on alternative routes for vaccine delivery, specifically aligning the route of vaccination with the natural route of TB infection using aerosol delivery methods (6) (7) (8) (9) . BCG has been shown to enhance protection against experimental M. tuberculosis infection when delivered intranasally or by aerosol to mice (10, 11) and as an aerosol to guinea pigs (12, 13) or rhesus macaques (14) . However, the previous aerosol BCG immunization studies did not investigate in detail the immunological mechanisms underlying this protection.
A successful TB vaccine will need to induce persistent memory T-cell populations. There is an established division of labor between effector T cells (TEM) able to migrate to peripheral tissues through the expression of tissue-specific homing markers to execute inflammatory functions and central memory T cells (TCM) that reside within secondary lymphoid tissues ready to proliferate and replenish the TEM pool (15) . The T-cell response to active TB infection has been shown to favor the TEM phenotype, with TCM more prevalent in latently infected individuals (16) . Vaccine-induced TEM responses have been associated with protection against viral pathogens (17) , and TEM populations have been investigated and detected following systemic BCG vaccination (18) . Hence, it has been hypothesized that the current BCG vaccination induces TEM populations capable of the short-term control of M. tuberculosis infection but poorly induces the TCM populations required for long-term protection (19) .
Currently there is no validated correlate of protection against M. tuberculosis infection, but a cell-mediated T-helper 1 (Th1) response from CD4 T cells (20) and probably a major histocompatability class (MHC) I restricted CD8 response (21) are known to be important for successful control of the disease. In the absence of a true correlate, functional markers such as gamma interferon (IFN-␥) expression are measured to assess vaccine immunogenicity. In recent years, the quality of the T-cell response has been highlighted as important to the induction of memory T cells (22) , and multifunctional CD4 cells expressing combinations of the cytokines IFN-␥, tumor necrosis factor alpha (TNF-␣), and interleukin-2 (IL-2) have been implicated both in the active phase of the disease (23) and as correlates of vaccine-induced protection (24) (25) (26) . However, there is also evidence contradicting the legitimacy of these multifunctional cells as markers of anti-TB protective immunity (27) , which highlights the likely complexity of the immune response required for tuberculosis immunity. Indeed, it is now clear that the CD4 T-helper response is diverse and includes cells of the Th17 lineage. IL-17 production has been implicated in the induction and maintenance of the Th1 response following BCG vaccination and recruitment of cells to the lung following infection with M. tuberculosis (28, 29) and correlates with improved outcome following M. tuberculosis exposure in nonhuman primates (NHP) (30) .
The NHP model has many advantages over other species for the study of potential TB vaccines. These include the similarity of primate anatomy, physiology, susceptibility to low-dose aerosol infection, and, crucially, immune response to those of humans (31, 32) . In this study, we used the rhesus macaque model to investigate mucosal and systemic immune responses induced following aerosol BCG vaccination. In doing so, we reveal features of the aerosol-induced immune response that may contribute to the enhanced protection reported in the literature and inform future vaccination strategies and the search for correlates of protection.
MATERIALS AND METHODS
Aerosolization of BCG and effect on vaccine viability. BCG was aerosolized by nebulization with the Omron MicroAIR device, and the effect of this on vaccine viability was investigated. One-milliliter solutions of BCG Danish strain 1331 (Statens Serum Institut [SSI], Copenhagen, Denmark) reconstituted in phosphate-buffered saline (PBS) were aerosolized through a sealed system to prevent loss of aerosol to the atmosphere, and cells were passively collected by condensation into sterile deionized water. The condensate was plated onto Middlebrook 7H11 selective agar containing oleic acid, bovine albumin, dextrose, and catalase (OADC) (bioMérieux, Basingstoke, United Kingdom) for enumeration of viable CFU. In parallel, CFU were measured in a nonaerosolized aliquot of identical BCG solution to enable quantification of any change in bacterial viability associated with the aerosolization process. To estimate the aerosol vaccination dose, losses associated with the nebulization apparatus and procedure were measured. BCG vaccine solution was nebulized through the Omron MicroAir device with an unsealed pediatric face mask, and the aerosol was collected in an all-glass impinger (AGI) (ACE Glass Inc., Vineland, NJ, USA) under conditions mimicking macaque inhalation and expiration. Viable CFU in collected aerosols were determined alongside those in nonaerosolized BCG solution as described above.
Experimental animals. Eight rhesus macaques (Macaca mulatta) of Indian origin aged between 4.6 and 5.2 years of age were obtained from an established United Kingdom breeding colony. The absence of a previous exposure to mycobacterial antigens was confirmed by tuberculin skin tests as part of the colony management procedures and by screening for IFN-␥ enzyme-linked immunosorbent spot (ELISpot) assay (MabTech, Nacka, Sweden) responses to purified protein derivative (PPD) (SSI, Copenhagen, Denmark) and pooled 15-mer peptides of early secreted antigen target 6 (ESAT-6) and 10- Keynes, United Kingdom) and a modified pediatric anesthesia mask. Vaccine doses were selected to be equivalent to or 1/10 of a standard adult intradermal dose after the expected losses in BCG titer associated with the aerosol delivery process were taken into account. BCG vaccine was prepared by adding 1 ml of PBS to each vaccine vial to give an estimated concentration of 2 ϫ 10 6 to 8 ϫ 10 6 CFU/ml. Multiple vials were pooled to ensure standardization between vaccinations, and 1/10 dose solutions were created by diluting this stock 1:10 with PBS before delivering 1 ml of the appropriate preparation to each animal.
Clinical assessment. Animals were sedated at two weekly intervals for blood sample collection and measurement of body weight and body temperature, red blood cell (RBC) hemoglobin levels, and erythrocyte sedimentation rates (ESR). RBC hemoglobin was measured using a HemoCue hemoglobinometer (HemoCue Ltd., Dronfield, United Kingdom), and the ESR was measured using the Sediplast system (Guest Medical, Edenbridge, United Kingdom). Animal behavior was observed throughout the study for contraindicators, including depression, withdrawal from the group, aggression, changes in feeding patterns, respiration rate, or coughing. Bronchoalveolar lavage (BAL) fluid was collected at 4-week intervals, as described previously (6) .
Immune response analysis. (i) IFN-␥ ELISpot assay.
Gamma interferon (IFN-␥) ELISpot assays were performed on peripheral blood mononuclear cells isolated from heparin anticoagulated blood using standard methods, as previously described (6) .
(ii) Intracellular cytokine staining. Intracellular cytokine staining (ICS) was performed on 1 ϫ 10 6 BAL fluid cells or peripheral blood mononuclear cells (PBMCs) in medium (R10) consisting of RPMI 1640 supplemented with L-glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 g/ml), and 10% heat-inactivated fetal bovine serum. These cells were stimulated with a 10 g/ml solution of CD28 and CD49d costimulatory antibodies (both from BD Biosciences, Oxford, United Kingdom) and 10 g/ml PPD (SSI, Copenhagen, Denmark), 5 g/ml staphylococcal enterotoxin B (SEB) (Sigma-Aldrich, Gillingham, United Kingdom), or R10 medium alone as a negative control. Intracellular cytokine staining to evaluate antigen-specific production of the cytokines IFN-␥, TNF-␣, IL-2, and IL-17 was performed as previously described (6) .
(iii) Immunophenotyping. Immunophenotyping was performed using 1 ϫ 10 6 freshly isolated PBMCs or BAL fluid cells incubated for 30 min at room temperature with optimal dilutions of the following fluorescent antibodies: CD3-AF700, CD4-allophycocyanin (APC)-H7, CD8-fluorescein isothiocyanate (FITC), CD95 PeCy7, CCR7-phycoerythrin (PE), CD29-APC, and CD49d-BV711 (all from BD Biosciences, Oxford, United Kingdom), CD28-BV421 (BioLegend, London, United Kingdom), and CD14-ECD and CD20-ECD (Beckman Coulter, High Wycombe, United Kingdom). The amine-reactive Live/Dead fixable red dead cell stain kit was from Life Technologies (Renfrew, United Kingdom). BD CompBeads (BD Biosciences) were labeled with the above fluorochromes and used as compensation controls. Following antibody labeling, cells and beads were washed by centrifugation and fixed in 4% paraformaldehyde solution (Sigma-Aldrich, Gillingham, United Kingdom) prior to flow cytometric acquisition.
(iv) Flow cytometric acquisition and analysis. Cells were analyzed using a four-laser LSR II flow cytometer (BD Biosciences, Oxford, United Kingdom). Cytokine-secreting T cells were identified using a forward scatter height (FSC-H) versus side scatter area (SSC-A) dot plot to identify the lymphocyte population, to which appropriate gating strategies were applied to exclude doublet events, nonviable cells, monocytes (CD14 ϩ ), and B cells (CD20 ϩ ). For ICS analysis, sequential gating through CD3 ϩ , CD4 ϩ , and CD8 Ϫ or CD3 ϩ , CD8 ϩ , and CD4 Ϫ cells was used before individual cytokine gates to identify IFN-␥-, IL-2-, TNF-␣-, and IL-17-producing subsets. For phenotyping analysis, CD4 and CD8 populations were identified using bivariate dot plots before assessment of homing marker expression using CD29 (␤1 integrin chain) versus CD49d (␣4 integrin chain) bivariate plots (see Fig. 8E and F). T-cell memory profiles were identified by gating on CD4 or CD8 populations with high surface staining for CD95, before differentiation of CD28 and CCR7 expression (see Fig. 6 and 7E to H). All data were analyzed using FlowJo (version 9.7.6; Tree Star, Ashland, OR, USA). Polyfunctional cells were identified using Boolean gating combinations of individual cytokine-producing CD4 or CD8 T cells. The software package PESTLE (version 1.7) was used for background subtraction to obtain antigen-specific ICS assay responses, and SPICE (version 5.35) was used to generate graphical representations of flow cytometry data (Mario Roederer, Vaccine Research Center, NIAID, NIH).
(v) Serum IgG ELISAs. Levels of anti-tuberculin PPD IgG in serum samples were measured by enzyme-linked immunosorbent assays (ELISAs). High protein binding capacity polystyrene plates (Fisher Scientific, Loughborough, United Kingdom) were coated with a 1 g/ml solution of tuberculin PPD (SSI, Copenhagen, Denmark) suspended in pH 9.5 carbonate-bicarbonate buffer (Scientific Laboratory Supplies, Hessle, United Kingdom). Plates were washed and blocked using PBS plus 5% dried milk powder (BD Biosciences, Oxford, United Kingdom) before addition of 2-fold serial dilutions of serum samples. Following incubation, the plates were washed and incubated with 0.3 g/ml goat anti-monkey IgG-horseradish peroxidase (HRP) (Insight Biotechnology Ltd., Wembley, United Kingdom). After further incubation and washing, the peroxidase substrate 3,3=,5,5=-tetramethylbenzidine (SurModics, Inc., Eden Prairie, MN, USA) was added to the wells, and the wells were incubated at room temperature for 10 min. The reaction was stopped by the addition of 2 M sulfuric acid (Fisher Scientific, Loughborough, United Kingdom), and the absorbance at 450 nm was measured immediately. Antibody titers were determined by linear regression of the sample dilution series and are expressed as arbitrary units relative to the mean prevaccination levels.
Necropsy. Before necropsy, animals were anesthetized with ketamine (15 mg/ml intramuscularly [i.m.]), weighed, and photographed, clinical data were collected, and exsanguination was performed via the heart, before termination by injection of a lethal dose of anesthetic (140 mg/kg Dolethal; Vétoquinol, Ltd., United Kingdom). A full necropsy was performed, and gross pathology was assessed. Samples of spleen, liver, kidneys, lymph nodes (hilar, inguinal, mesenteric, axillary, and colonic), tonsil, brain, olfactory bulb, heart and pericardium, small intestine (ileum, jejunum, and duodenum), transverse colon, eye, and the upper left lung lobe were removed, dissected on sterile trays, and placed into formalinbuffered saline for gross pathology and histopathology analysis.
Histopathology. Representative sections from the tissues described above were processed to paraffin wax, cut at 5 m, and stained with hematoxylin and eosin (H&E) for microscopic examination. Pathology analysis was performed blinded to the vaccination dose and group. To estimate the aerosol vaccine dose, BCG was aerosolized through the unsealed nebulizer with a pediatric face mask and actively collected under conditions mimicking macaque respiration. Stock solutions of BCG had viable CFU counts of 5.35 ϫ 10 5 CFU/ml, whereas the mean CFU collected from four repeat nebulizations of BCG solution was 4.49 ϫ 10 4 CFU/ml Ϯ 2.37 ϫ 10 4 CFU/ml. This represented a 1.08-log 10 reduction in viable BCG CFU/ml, implying that the aerosol BCG dose would be approximately 10-fold less than the titer of the nebulized BCG solution.
Safety of aerosol-delivered BCG. There were no observed perturbations beyond the normal ranges in body weight, temperature, peripheral lymph node size, red cell hemoglobin concentration, or erythrocyte sedimentation rate following aerosol BCG vaccinations.
Histopathology analysis by H&E staining of secondary lymphoid tissues did not reveal any adverse findings attributable to the BCG vaccination or route of administration.
The frequency of systemic PPD-specific IFN-␥-secreting cells increases following aerosol BCG vaccination. Systemic immune responses induced by aerosol BCG vaccination were profiled using an ex vivo IFN-␥ ELISpot assay. Increases in PPDspecific IFN-␥ spot-forming unit (SFU) frequencies were observed from 8 weeks after aerosol vaccination and reached significance at weeks 10 and 13 in both vaccination groups (P ϭ 0.03) (Fig. 1 ). Significant differences were not detected between i.d.-equivalent and lower-dose aerosol vaccination groups when ELISpot assay AUCs measured across the study time course were compared by the Mann-Whitney U test (P ϭ 0.34).
CD4 and CD8 T-cell responses measured by ICS are of Th1 and Th17 lineage following aerosol BCG vaccination. Antigenspecific production of the cytokines IFN-␥, TNF-␣, IL-2, and IL-17 by CD4 and CD8 T cells was measured throughout the study by multiparameter ICS (Fig. 2 and 3) . Cytokine production by CD4 and CD8 T cells in BAL fluid and PBMCs was characteristic of a Th1-and Th17-type response. A clear dose response was evident in both the mucosal and systemic T-cell populations, with significantly greater frequencies of IFN-␥-, IL-2-, and TNF-␣-producing CD4 cells (P ϭ 0.02) and IFN-␥-producing CD8 T cells (P ϭ 0.02) detected in BAL fluid 13 weeks after aerosol BCG vaccination equivalent to a standard i.d. dose.
Peripheral and mucosal multifunctional T-cell response profiles induced by aerosol BCG vaccination. Mucosal and systemic polyfunctional profiles of CD4 and CD8 T cells producing combinations of the cytokines IFN-␥, IL-2, and TNF-␣ following aerosol BCG vaccination were measured throughout the study. CD4 responses induced by aerosol vaccination in BAL fluid cells were significantly above the prevaccination levels in four distinct profiles: IFN-␥, IL-2, and TNF-␣ triple-positive cells (P ϭ 0.02), IFN-␥ and TNF-␣ dual-positive cells (P ϭ 0.02), and IFN-␥-or TNF-␣-producing single-positive cells (P ϭ 0.02) (Fig. 4A and B) . A clear dose response was apparent between the vaccination groups in terms of mucosal CD4 T cells, with the frequency of triple-positive cells (P ϭ 0.02), IFN-␥ and TNF-␣ dual-positive cells (P ϭ 0.02), and IFN-␥ only-producing cells (P ϭ 0.02) significantly greater following vaccination via the aerosol route with a dose equivalent to a standard i.d. vaccination. CD8 T cells in BAL fluid and PBMCs were found to produce IFN-␥ or TNF-␣ or both cytokines simultaneously (Fig. 5A to D) and were present 4 weeks following aerosol vaccination. CD8 T cells producing TNF-␣ increased significantly in BAL fluid and were detected in PBMC samples following aerosol BCG vaccination.
Aerosol BCG vaccination leads to expansion of systemic central memory populations, whereas mucosal T cells remain polarized in an effector memory phenotype. Central and effector memory T-cell populations are identified in the rhesus macaque by expression of cell activation markers such as CD95, followed by differential expression patterns of the costimulatory receptor CD28 and lymph node homing marker CCR7. Therefore, the central-to-effector memory axis was determined as CD28 ϩ CCR7 (34, 35) . Using this classification, T-cell memory profiles were assessed on cells isolated from BAL fluid and PBMCs at regular intervals throughout the study. CD4 and CD8 T cells from BAL fluid remained polarized in an effector T-cell phenotype throughout the study. CD4 T cells primarily occupied a TransEM profile; CD8 restricted cells were approximately evenly split between the TransEM and the fully differentiated TEM phenotype (Fig. 6A and B and 7A and B) . A similar pattern was observed in CD4 and CD8 effector memory subsets isolated from peripheral blood but was accompanied by significant increases in TCM frequency. This TCM expansion was most pronounced in the CD4 subset and was seen in both aerosol vaccination groups. Expanded TCM populations remained elevated following aerosol BCG vaccination with a dose equivalent to the standard i.d. BCG vaccination, whereas the population had contracted and was significantly lower in the 1/10 dose group 13 weeks after vaccination (P ϭ 0.02) (Fig. 6C and D and 7C and D) .
␣4␤1 integrin homing markers are highly expressed by mucosal T cells. T-cell expression patterns of the ␣4 and ␤1 integrin chains were investigated as putative T-cell lung homing markers (Fig. 8) . Dose-related differences in expression profiles were not observed following aerosol vaccination; therefore, data from the high-and lower-dose vaccination groups were combined for analysis purposes. The ␣4␤1 integrin chains were highly expressed on CD4 and CD8 T cells isolated from BAL fluid prior to vaccination and remained consistently high throughout the study, with a significant increase in ␣4␤1 coexpression on CD4 T cells 13 weeks following vaccination (Fig. 8A and C) . The expression patterns on PBMCs were more varied and generally remained consistent throughout the study, although a trend for reduced ␣4␤1 detection in the CD8 subset was noted 4 weeks after vaccination and was accompanied by a significant increase in the proportion of ␣4␤1 double-negative cells at this time point (Fig. 8B and D) .
Anti-tuberculin PPD IgG titers measured in serum increase following aerosol BCG vaccination. Levels of tuberculin PPD-specific IgG were measured in serum samples at selected time points throughout the study using a PPD ELISA. Median anti-PPD IgG titers increased in both vaccination groups relative to the prevaccination levels but had subsided 10 weeks later in the lower-dose vaccination group. Titers remained elevated in animals receiving aerosol vaccination equivalent to a standard i.d. dose (Fig. 9 ).
DISCUSSION
Despite a concerted global effort, TB remains a leading cause of mortality from an infectious agent. In recent years, the search for novel vaccines to improve upon the protection afforded by conventionally delivered BCG has begun to focus on alternative routes for vaccine delivery. Aerosol delivery of TB vaccines to the mucosal surface of the lung is a rational approach for localizing a vaccine-induced response at the primary site of infection. Such an approach has proven practical and effective in the context of measles vaccination (36) and has recently proven safe and immunogenic in clinical trials of the novel TB vaccine MVA85A (7).
Aerosol-delivered BCG vaccination has previously been shown to afford enhanced protection against inhaled M. tuberculosis infection in the rhesus macaque (14) . However, these studies did not describe the host response underpinning this protection. With this assessment of the immunogenicity of aerosol BCG vaccination, we highlight features of the mycobacterium-specific T-cell response induced via the mucosal vaccination route that may contribute to the enhanced protection observed in previous studies. Moreover, in comparison with recently published studies describing equivalent immunogenicity measures applied following i.d. BCG vaccination in age-matched rhesus macaques, a comparison can be drawn between the immune responses induced by each vaccination route (6) . Multifunctional T-cell responses are thought to be an important component of a protective immune response against intracellular pathogens, including M. tuberculosis (24) (25) (26) , and have been shown to be involved during the active phase of tuberculosis infection (23) . Our results show that polyfunctional CD4 T cells are detected in the lung following aerosol vaccination and that the functional repertoire of CD4 and CD8 T cells induced by aerosol BCG was consistent with that reported in our prior studies of i.d. BCG immunogenicity. However, the frequency of antigen-specific cells was observed to increase at later time points following aerosol vaccination (6, 32) . In addition, aerosol vaccination also induced TNF-␣-secreting CD8 populations detectable at the mucosal surfaces or in the periphery. As antigen-specific TNF-␣ production has been implicated as a protective factor in the control of tuberculosis (37, 38) and anti-TNF-␣ therapy has been demonstrated to induce reactivation of latent infection (39, 40) , this could prove to be an important factor in the protection imparted by aerosol BCG vaccination.
Delayed T-cell activation is an established phenomenon associated with M. tuberculosis infection and is often in contrast with the kinetics observed following infection with comparable intracellular pathogens and viruses (41) (42) (43) (44) (45) . Our study suggests that the route of BCG vaccination has a significant impact on the kinetics of the cell-mediated response. This was seen as a delay in the peripheral response measured by the IFN-␥ ELISpot assay, which was detected approximately 8 weeks following aerosol vaccination, whereas intradermally delivered BCG responses typically occur by week 4 (6, 32) . Moreover, a similar trend was observed in CD4 T-cell cytokine production, including that of polyfunctional T cells, measured in BAL fluid and PBMCs, which was delayed relative to the cytokine production observed in prior i.d. BCG vaccination studies (6) . This is also a notable retarding of T-cell induction relative to that observed following M. tuberculosis infection via the respiratory route, where PPD-specific IFN-␥ SFU are usually detected within 4 weeks of infection in immunologically naive animals (32) . Furthermore, such delayed activation of the mycobacterium-specific response may explain the protection observed in prior studies by Barclay et al. (14) , as their study design delivered the M. tuberculosis challenge 8 weeks following vaccination, which would be during the peak of the primary aerosol BCGinduced vaccine response.
Induction of immunological memory is an essential feature of a successful vaccine. BCG is primarily administered to infants or adolescents and confers protection against disseminated childhood forms of tuberculosis (2) . However, the longevity of this protection is thought to wane beyond the adolescent years, suggesting that intradermally delivered BCG weakly induces longlived memory T-cell responses (3, 4) . Our T-cell memory phenotyping analysis shows that aerosol-delivered BCG leads to significant expansion of circulating CD4 central memory populations. This expansion persisted for at least 3 months following vaccination, after which point there was evidence for contraction of the TCM population in the lower-dose vaccination group. While different models exist to describe the development pathway of memory T-cell populations (46, 47) , most agree that induction of the TCM subset leads to long-lived populations residing within secondary lymphoid tissues. However, we recognize that ours is a relatively short-term study and that longer time scales are required to assess the longevity of these cells beyond the primary phase of the vaccine response. Furthermore, measurement of functional markers such as cytokine production, cytotoxicity, and proliferation within the memory T-cell subsets is required to assess the antigen-specific recall capacity of these cells.
In agreement with previous observations, our data confirm that the T-cell repertoire within the lung is biased toward an effector phenotype (35, 48) . This is further supported by the high levels of Th1 and Th17 effector cytokines we detected in cells isolated from BAL fluid. The homing capacity to peripheral organs is a key feature of TEM (47), and expression of the ␣4␤1 integrin cell surface adhesion markers has been linked with T-cell enrichment in the lung (49) and lung localization of PPD-specific IFN-␥-producing CD4 cells in M. tuberculosis-infected patients (50) . To investigate whether these markers could be used as correlates of mucosal immunity, we followed the surface expression dynamics of the ␣4␤1 integrin chains following aerosol BCG vaccination. Our data confirm that CD4 and CD8 T cells isolated from BAL wash fluid coexpress ␣4␤1 at a high level, supporting the use of these markers as a measure of lung homing capacity. However, expression frequencies remained unchanged in both BAL fluid and PBMC samples following vaccination. We believe this highlights the limitation of measuring global frequencies of these markers, which inevitably reduces an assay's sensitivity to detect small changes within the total T-cell pool. Therefore, characterization of homing marker expression on cells executing antigenspecific functions should be a priority for future studies.
Aerosol delivery of vaccines is a practical proposition in the clinical setting, holding many advantages over conventional needle-based approaches. The safety of delivering novel TB vaccines to rhesus macaques and healthy human volunteers has recently been established (6) (7) (8) (9) . However, despite the excellent safety record of BCG, particular caution is warranted in the context of delivering live, attenuated bacilli to the lung and nasopharyngeal surfaces. The primary objective of this study was to characterize the immunological profiles induced by aerosol BCG and contrast these with existing i.d. BCG immunogenicity data to elucidate potential correlates of mucosal immunity. In addition, we are able to report that aerosol BCG was well tolerated, with no contraindications observed in the clinical parameters measured. Moreover, histopathology analysis of secondary lymphoid tissues did not reveal any adverse findings attributable to the BCG vaccination or route of administration. However, further studies are required to demonstrate the safety of this approach before trials in human volunteers and immunocompromised individuals. Consequently, we intend to further investigate the efficacy of aerosol BCG vaccination and characterize the events following low-dose experimental M. tuberculosis infection to confirm the protection reported in the literature and further interrogate correlates of mucosal immunity and protection.
